Combination of DCE-MRI and NME-DWI via Deep Neural Network for Predicting Breast Cancer Molecular Subtypes
Clinical Breast Cancer · 2024
DOI: 10.1016/j.clbc.2024.03.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Zhi-Chang Ba und 8 weiteren Autor:innen. Beteiligte Einrichtung: Imaging Center, Harbin Medical University Cancer Hospital, Harbin, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Neural Networks, Computer, Diffusion Magnetic Resonance Imaging, Contrast Media. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Harbin Medical University Cancer Hospital, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: To explore whether the combination of dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and nonmono-exponential (NME) model-based diffusion-weighted imaging (DWI) via deep neural network (DNN) can improve the prediction of breast cancer molecular subtypes compared to either imaging technique used alone. PATIENTS AND METHODS: This prospective study examined 480 breast cancers in 475 patients undergoing DCE-MRI and NME-DWI at 3.0 T. Breast cancers were classified as follows: human epidermal growth factor receptor 2 enriched (HER2-enriched), luminal A, luminal B (HER2-), luminal B (HER2+), and triple-negative subtypes. A total of 20% cases were withheld as an independent test dataset, and the remaining cases were used to train DNN with an 80% to 20% training-validation split and 5-fold cross-validation. The diagnostic accuracies of DNN in 5-way subtype classification between the DCE-MRI, NME-DWI, and their combined multiparametric-MRI datasets were compared using analysis of variance with least significant difference posthoc test. Areas under the receiver-operating characteristic curves were calculated to assess the performances of DNN in binary subtype classification between the 3 datasets. RESULTS: The 5-way classification accuracies of DNN on both DCE-MRI (0.71) and NME-DWI (0.64) were significantly lower (P < .05) than on multiparametric-MRI (0.76), while on DCE-MRI was significantly higher (P < .05) than on NME-DWI. The comparative results of binary classification between the 3 datasets were consistent with the 5-way classification. CONCLUSION: The combination of DCE-MRI and NME-DWI via DNN achieved a significant improvement in breast cancer molecular subtype prediction compared to either imaging technique used alone. Additionally, DCE-MRI outperformed NME-DWI in differentiating subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Imaging Center, Harbin Medical University Cancer Hospital, Harbin, China.
- Division of Respiratory Disease, Fourth Affiliated Hospital of Harbin Medical University, Yiyuan street No.37, Nangang District, Harbin, China. Electronic address: sangxiqiao@126.com.
- Imaging Center, Harbin Medical University Cancer Hospital, Harbin, China. Electronic address: zixiangkuai@126.com.
Förderung
- Harbin Medical University Cancer Hospital
- National Natural Science Foundation of China
Zitieren
APA
Ba, Z. C., Zhang, H. X., Liu, A. Y., Zhou, X. X., Liu, L., Wang, X. Y., Nanding, A., Sang, X. Q., & Kuai, Z. X. (2024). Combination of DCE-MRI and NME-DWI via Deep Neural Network for Predicting Breast Cancer Molecular Subtypes. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.03.006
Vancouver
Ba ZC, Zhang HX, Liu AY, Zhou XX, Liu L, Wang XY, et al. Combination of DCE-MRI and NME-DWI via Deep Neural Network for Predicting Breast Cancer Molecular Subtypes. Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.03.006
BibTeX
@article{Ba2024,
author = {Ba, Zhi-Chang and Zhang, Hong-Xia and Liu, Ao-Yu and Zhou, Xin-Xiang and Liu, Lu and Wang, Xin-Yi and Nanding, Abiyasi and Sang, Xi-Qiao and Kuai, Zi-Xiang},
title = {Combination of DCE-MRI and NME-DWI via Deep Neural Network for Predicting Breast Cancer Molecular Subtypes},
journal = {Clinical Breast Cancer},
year = {2024},
doi = {10.1016/j.clbc.2024.03.006}
}
EUVIMED